China's 15th Five-Year Plan
Changes the Economics of
Western Life Sciences
Reimbursement, procurement, localization, and reference pricing are now linked. Weak China decisions no longer just underperform. They destroy value in Europe and the United States. For boards making China pricing, market access, licensing, or partnership decisions in H2 2026.
​
Five Shifts Your Board Needs to Know
1. Pillar-industry status Biopharma and advanced medtech designated as "emerging pillar industries" with coordinated state investment. China's biomanufacturing market: $157B (NDRC, March 2026).
​
2. Dual-track reimbursement Category C protects breakthrough therapies with DRG/DIP exemptions. The basic NRDL extracts 60%+ price cuts — which cascade to European reference pricing (NHSA; Greenberg Traurig, Feb 2026).
3. Licensing reversal China's out-licensing: $137.7B in announced deal value (PharmaSource, Jan 2026). 23% of the global oncology pipeline (IQVIA, Feb 2025). European acquirers conspicuously underrepresented.
4. Medtech localization Device VBP: 80%+ cuts in stents, orthopedics, spinal (NHSA; Simon-Kucher 2025). "Innovative device" status tied to Chinese patents and local production. Import-only is structurally unviable.
5. Data sovereignty limits regulatory convergence 30-day IND and ICH alignment bring NMPA closer to global standards. But HGR controls and data localization require permanent in-China operations.
​
The Reference Pricing Cascade A single China pricing decision can destroy more value in your core markets than China generates in revenue. Companies accepting deep NRDL cuts face cascading price compression in European markets — and under the renewed US MFN direction, in the United States. SILREAL advised a European mid-cap biotech to restructure its China entry — avoiding €18–24M in reference pricing losses while preserving a viable licensing path.
What's Inside the Full Analysis
- 14th vs. 15th FYP comparison — nine dimensions - Category C vs. NRDL reimbursement mechanics
- "Do Not Proceed" case — €18–24M European revenue destruction
- $137.7B licensing reversal — European gap analysis - BIOSECURE and EU FDI screening navigation
- Medtech: Device VBP, Order 551, EU reciprocity options
- 10-question Decision Checklist with scoring bands
About the Author
Chenchao Liu | Managing Director, SILREAL GmbH, Berlin Advises AstraZeneca, Bayer, and the German Federal Ministry of Health on healthcare policy, regulation, and market access across Europe, China, and the United States.​
​
Download the Briefing The analysis your board needs before any China market access, pricing, or licensing decision in 2026.